EZEM E-Z-EM (MM)

E-Z-EM, Inc. (NASDAQ:EZEM) today announced that the U.S. Army Space & Missile Defense Command (USASMD) has placed an additional order for the Company�s RSDLTM personal skin decontamination product. The approximately $8 million order is the second such order placed by the U.S. Department of Defense (DoD) since it issued Milestone C approval for the product, and is the largest single order for RSDL the Company has received to date. The Company expects to ship and invoice for the order by April 2008 with resulting revenues recognized as the product is shipped. Commenting on the announcement, Anthony A. Lombardo, President and CEO of E-Z-EM, said, �We are especially pleased with this order as the DoD has exceeded our original estimate for procurement of RSDL in the government�s 2007 fiscal year. Additionally, we are pleased the DoD placed this follow-on order so quickly after their initial procurement of RSDL in March of 2007. We believe this demonstrates the importance with which the DoD views RSDL and its ability to provide our troops with improved protection against chemical weapons agents.� About RSDL RSDL is a patented, broad spectrum skin decontamination product intended to remove or neutralize chemical warfare (CW) agents or T2 toxins from the skin. RSDL was originally developed�and patented by�Defence Research and Development Canada, an agency within the Canadian Department�of National Defence,�for�use by the Canadian Forces. RSDL has since been adopted by several military services around the world. RSDL is produced by EZEM�under a�License�with�Defence Research and Development Canada (DRDC). RSDL has since been adopted by several military services around the world. RSDL received Milestone C approval from the Joint Program Executive Office for Chemical Biological Defense (JPEO-CBD), a decision that cleared the way for procurement by the individual service branches of the DoD. The US Food and Drug Administration (FDA) issued 510(k) clearance for RSDL in March of 2003. The U.S. DoD began final configuration testing on the product in November of 2003 and authorized the sale of RSDL to first responder organizations in September of 2004. In September 2006, RSDL was awarded Safety Act certification by the U.S. Department of Homeland Security (DHS), which extends certain liability protections to the Company and its suppliers and customers (whether public or private) in the event RSDL is used in response to a terrorist incident. About E-Z-EM, Inc. E-Z-EM is a publicly traded healthcare company founded in 1962, and has since established itself as one of the most recognized brands in diagnostic imaging of the GI tract. From the first barium contrast systems introduced over 40 years ago, to today's advanced products for CT imaging and virtual colonoscopy, E-Z-EM has continually developed innovative imaging and diagnostic solutions for physicians treating GI diseases. E-Z-EM is also a respected contract manufacturer of specialized liquid products, and has been the exclusive global manufacturer of RSDL� since 1996. In April of 2005, E-Z-EM completed the acquisition of all assets associated with RSDL, and now is the product's exclusive worldwide marketer to first-responder organizations and military services. The statements made in this document contain certain forward-looking statements. Words such as �expects,� �intends,� �anticipates,� �plans,� �believes,� �seeks,� �estimates� or variations of such words and similar expressions, are intended to identify such forward-looking statements. The forward-looking statements contained in this release may involve numerous risks and uncertainties, known and unknown, beyond the Company�s control. Such risks and uncertainties include: the ability of the Company to develop its products, placement of further DoD orders for RSDL, the timing of revenue recognition for RSDL and its impact on the Company's financial results, the impact on future sales of SAFETY Act designation and certification for RSDL, future orders of RSDL by first responder organizations, general military and first-responder market acceptance and sales of RSDL, future actions by the FDA or other regulatory agencies, overall economic conditions, general market conditions, price increases of raw materials and components, foreign currency exchange rate fluctuations as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on its Form 10-K for the fiscal year ended June 3, 2006 and its Form 10-Q for the quarter ended March 3, 2007. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements, and investors are cautioned not to place undue reliance on the forward-looking statements included in this release.